RespireRx Pharmaceuticals Inc (fka RSPI)

[Menace212]

‘The valua7on report came in at mul7ples of US$ 25
million so we priced at 90% x 25 million or US$ 22.5 mm
1. The $1.35 that the investor referred to is Australian dollars, not US
and equates to US$ 0.90/share.’

Read that in the 8-k back in august 2023. Checks out. The entirety of their response seems sincere and genuine. Also the respondent equates our current situation back to their 2014 situation where they didn’t achieve current status due to miss flings in June. And was able to update their fillings by December. So one can conclude by December or early next year fillings should be released especially if they have them ready like they say.

However now we know this was not a strategy or a tactic to enter into EM to potentially reassert their assets. They really did not have money lol. I must say I’m bit frustrated at that point, however management not taking salary clearly shows their deepened investment into the actualization of their research into real products. That is indeed endearing especially noting the fact they been working on this for a better part of 10 years.